Home > Healthcare > Pharmaceuticals > Finished Drug Form > Dermatology Drugs Market

Dermatology Drugs Market Trends

Report ID: GMI6311
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Dermatology Drugs Market Trends

Dermatologists were exploring the use of drug combinations and sequential therapy approaches to enhance treatment outcomes in certain skin conditions. Combining different classes of drugs or using them in a stepwise manner showed promise in achieving better disease control. In addition, biologic drugs, particularly monoclonal antibodies targeting specific cytokines or immune pathways, are gaining significant traction in the treatment of various autoimmune skin conditions. Drugs like TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors are becoming the standard of care for moderate to severe psoriasis and other inflammatory skin diseases due to their high efficacy and targeted approach.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Dermatology drugs industry size reached USD 27.1 billion in 2022 and will record USD 73.5 billion by the end of 2032 owing to the increasing prevalence of skin disorders along with the higher advancements in research and development

Parenteral injection route of administration segment is expected to witness 10.5% CAGR from 2023-2032 driven by the rising obligation to offer accurate and targeted medication administration

The hospital pharmacies distribution channel segment held 76.5% of the dermatology drugs industry share in 2022 due to the robust presence of specialized departments as well as diagnostic devices and treatment devices

North America size is expected to be valued at USD 10.7 billion by 2032 driven by the strong presence of well-established and advanced healthcare infrastructure in the region